Performance Of Economic Analysis Research Articles

APPLICATION OF THE GROWTH ACCOUNTING METHOD FOR THE CONSTRUCTION INDUSTRY

As the growth accounting method can suggest research benefits, this paper is dedicated to the application of the method in the construction industry. The lack of methodologies for the application of the method in the less developed countries has necessitated the design of the methodology presented in the paper. Once the methodology is composed, comparable results can be obtained on the fulfilment of international academic standards. The paper presents the main methodological problems faced by the author while working on the problem. In addition, it enables the identification of the proximate sources of growth as well as the performance of economic analysis from a comparative perspective of countries at different stages of development. The scientific merit of the paper – the entire group of intangible capital rather than only software will correspond to knowledge based capital. The results suggest that Lithuania is in a rather strong position in terms of productivity growth, but the same could not be said when considering the structure of its main determinants compared with the more developed countries.

Economic analysis of randomized, controlled trials.

To facilitate the comparison of different treatment strategies, measures have been developed that bring together clinical, quality-of-life, and economic outcomes into summary measures such as the quality-adjusted life year, cost-effectiveness, and cost-utility ratios. A number of different types of economic evaluations have been developed, including cost-minimization, cost-effectiveness, and cost-utility analyses. Performance of economic analyses in association with randomized, controlled trials (RCT) has gained increasing enthusiasm in recent years. However, economic measures in RCTs are often outcomes of secondary interest and associated with frequent missing data and inadequate sample size. Variability in the cost measures used and the lack of agreement on clinically meaningful cost differences further limit the conclusions derived from such studies. Economic analyses should be limited to large trials with important trade-offs between efficacy and cost. The strengths and limitations of such analyses are discussed, and guidelines are offered for proper economic analyses in randomized, controlled trials.